Purpose While FDG PET/CT for the evaluation of nasopharyngeal carcinoma (NPC) in adult patients has documented advantages and disadvantages compared with conventional imaging, to our knowledge, no studies of FDG PET/CT for the evaluation of NPC in pediatric patients have been performed. In this investigation, we studied the utility of FDG PET/CT in children with NPC. Methods The study group comprised 18 children with biopsyproven NPC who underwent FDG PET/CT and MRI (total 38 pairs of images). All baseline and follow-up FDG PET/CT and MRI studies were independently reviewed for restaging of disease.
Introduction
Nasopharyngeal carcinoma (NPC) is uncommon in children, with an incidence of only 0.1-1.5/1,000,000 per year in the US [1] . NPC is classified pathologically into three subtypes: type I, or keratinizing squamous cell carcinoma, the most common form in the US, often associated with alcohol and tobacco use; type II, or nonkeratinizing squamous cell carcinoma; and type III, or undifferentiated carcinoma [2] . Unlike in adults, type III is the most common subtype in children, while type I is the least common [3] . Children with NPC usually present with painless cervical lymphadenopathy [3] . The median age at diagnosis is 13 years. NPC may extend into the skull base and cause dysfunction of cranial nerves VI and XII, resulting in diplopia or dysphonia. The differential diagnosis includes primary and secondary tumors that may involve the nasopharynx, such as rhabdomyosarcoma and non-Hodgkin's lymphoma. Treatment includes chemotherapy and radiotherapy. The outcome in children is usually better than in adults.
Current methods for evaluating the disease at diagnosis and follow-up include CT, MRI, and bone scan. MRI is the preferred imaging modality for determining the extent of locoregional disease because of its excellent delineation of anatomic detail [4] . Investigators have recently utilized FDG PET alone or combined with CT (FDG PET/CT) to evaluate patients with NPC. The advantages of FDG PET are that it can provide semiquantitative information about the functional activity of the tumor, detect areas of involvement that may be overlooked by MRI, distinguish active tumor from scar tissue, and evaluate the whole body in a single imaging session. Some studies have found that FDG PET or FDG PET/ CT can contribute to staging [5] [6] [7] [8] , and has high sensitivity and specificity in diagnosing residual and recurrent disease [9] [10] [11] . There are also studies, however, that have shown that FDG PET or FDG PET/CT may not provide additional information beyond MRI and has low spatial resolution and high false-positive rate [12, 13] . The value of FDG PET/CT compared with conventional imaging in patients with NPC, therefore, remains inconclusive. These studies were composed largely of adults with only a few adolescents. Whether these data are applicable to children is uncertain, especially in view of the differences between children and adults in NPC biology. We performed the current study to evaluate the utility of FDG PET/CT compared with MRI for staging and follow-up in pediatric patients with NPC.
Methods
With institutional review board approval, we reviewed the medical records and imaging studies of all patients younger than 18 years with biopsy-proven NPC who underwent FDG PET/CT and treatment at St. Jude Children's Research Hospital from January 2003 through June 2009. We report the demographics, histopathology, imaging findings, treatments, and outcomes.
Treatment of patients
Patients were treated with three cycles of induction chemotherapy with cisplatin and 5-fluorouracil followed by concurrent radiotherapy and chemotherapy with cisplatin or chemoradiotherapy up-front followed by adjuvant chemotherapy. Radiation therapy was delivered with a conformal or intensity-modulated technique to cumulative doses of 6,120-6,600 cGy. Amifostine was used for salivary gland protection and renal protection as tolerated by patients.
Imaging protocol and review
For FDG PET/CT examinations, 5.5 MBq/kg [ 18 ]F-FDG (maximum 444 MBq) was injected intravenously following an overnight fast, or a minimum 4-h fast for afternoon studies. Blood glucose was determined prior to injection of [ 18 ]F-FDG and was normal. Patients were kept in a quiet dark room after injection and encouraged to remain recumbent with their arms resting at their sides and relaxed. Transmission CT images for attenuation correction and lesion localization, and PET emission images were acquired approximately 1 h later using a GE Discovery LS PET/CT system (GE Medical Systems, Waukesha, WI) with the patients' arms at their sides. CT acquisition parameters were slice thickness 0.5 cm, tube rotation 0.8 s, table speed 1.5 cm/rotation, pitch 1.5:1, 120 kV, 90 mA, with dose modulation. PET images were obtained from the top of the skull through the feet for 5 min per bed position in 2-D mode with the patients' arms at their sides. Images were reconstructed using standard vendor-supplied software. FDG PET/CT scans for each patient were reviewed by two nuclear medicine physicians without knowledge of clinical information. SUV max was determined manually from regions of interest placed over the tumor activity in multiple planes. The size of the regions of interest depended on the size of the tumor activity. There was no minimum size. The background was that of the surrounding noninvolved tissue. Uptake was considered abnormal if it was increased above that of the surrounding background and could not be explained by accumulation in a normal structure. Since all the studies were performed on PET/CT units, brown adipose tissue could be identified on the CT scan as areas of low attenuation in typical locations. MRI examinations of the neck were obtained using head and neck matrix coils to image the area from approximately the superior level of the temporal lobes to the sternal notch. The examinations consisted of unenhanced spin-echo sagittal T1-weighted, spin-echo axial T1-weighted, spin-echo coronal T1-weighted, fast spin-echo axial proton density, fast spinecho axial T2-weighted, and coronal STIR pulse sequences. Axial and coronal T1-weighted pulse sequences were also obtained using the parameters given above following intravenous administration of Gd-DTPA gadodiamide (Omniscan, GE Healthcare, Princeton, NJ) or gadopentate dimeglumine (Magnevist, Bayer Healthcare, Wayne, NJ). Fat saturation was used for the images acquired after gadolinium administration for one of the studies conducted at our institution and subtraction of T1-weighted images from before and after contrast agent administration was performed for all the other examinations obtained at our facility. Of 38 pairs of images 25 were obtained on a 1.5-T MRI system (either a Siemens Symphony or an Avanto unit), 12 were obtained on a 3-T MRI system (Siemens Trio), and 1 was obtained on a 1.5-T Philips Intera Achieva MRI unit at an outside institution. Fat saturation was used for the images obtained after contrast agent administration submitted with this outside examination.
One experienced pediatric neuroradiologist reviewed the MRI studies without knowledge of the clinical information. The size of the tumor was reported as the maximum anteroposterior or transverse diameter in the axial plane. Jugulodigastric and retropharyngeal lymph nodes (LNs) were considered metastatic if their short-axis diameter in the axial plane was greater than or equal to 1.1 cm or 6 mm, respectively [14] . LNs measuring greater than or equal to 1.0 cm in all other areas were considered metastatic. These size criteria for cervical LNs reflect those widely used in the literature [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Any LN with necrosis and groups of three or more borderline-sized LNs also qualified as metastatic [13, 15] . The presence of extranodal metastases was also assessed with a bone scan and a chest CT scan, which form part of the conventional imaging protocol. In this study, patients with baseline scans were restaged by conventional imaging (MRI, chest CT scan and bone scan) or FDG PET/CT independently according to the most recent version of the AJCC NPC staging classification [22] . For follow-up imaging, a false-positive result was defined as a residual abnormality that was not shown concurrently with the other imaging modality, subsequently disappeared or remained stable, or was determined by biopsy not to be malignant. A false-negative result was defined as the absence of a lesion with one imaging modality that was seen concurrently with the other imaging modality and that subsequently progressed or was confirmed by biopsy to be malignant.
EBV-VCA (Epstein-Barr virus viral capsid antigen) immunoglobulin levels were recorded for correlation with tumor uptake of FDG.
Statistical analysis
The agreement between FDG PET/CT and conventional staging was measured using Cohen's kappa [23] . The maximum value of 1 indicates that the measurements are in complete agreement. Landis and Koch interpret kappa as follows: <0 (no agreement), 0 to 0.2 (slight agreement), 0.2 to 0.4 (fair agreement), 0.4 to 0.6 (moderate agreement), 0.6 to 0.8 (substantial agreement), 0.8 to 1.0 (almost perfect agreement) [24] . Because of the small sample size, AJCC substages were dropped for some analyses. The Wilcoxon signed-ranks test was used to test the difference between FDG PET/CT and MRI measurements. The Jonckheere-Terpstra test was used to analyze the association between SUV max and staging. Spearman's rank correlation was used to test the association between SUV max and size of the tumor. The binomial test was used to compare LNs found by FDG PET/CT and MRI.
Results

FDG PET/CT and MRI performed in 18 patients from January 2003 through June 2009 (total 38 pairs of images).
All patients also had a chest CT scan and 17 patients had a bone scan at diagnosis. Their characteristics are shown in Table 1 . All patients had cervical lymphadenopathy at presentation. None had distant metastases according to the chest CT and bone scans. One patient had metastatic relapse in the lungs and mediastinum at 9 months after initial diagnosis and died at 2.6 years after diagnosis. The remaining patients were alive in continuous remission at the time of this report with a median follow-up of 4.5 years (range 2.0-9.7 years).
Of the 18 patients, 14 (78%) had both FDG PET/CT and MRI scans at baseline. Of these 14 patients, 6 also had a follow-up FDG PET/CT scan, with 5 patients having paired MRI for comparison. Four patients only had follow-up FDG PET/CT scan without a baseline FDG PET/CT scan because they were initially diagnosed in another institution before referral to us, and three of them had a paired MRI scan for comparison. All patients with baseline studies were alive without disease at the last follow-up. For the 14 patients with both FDG PET/CT and MRI scans at baseline, the scans were performed a median of 2.5 days apart (range 0-12 days apart). In three patients FDG PET/ CT scans were obtained 4-6 days after initiation of chemotherapy. No substantial head motion was noted, indicating good alignment of the PET and CT images Table 2 shows the size of the primary tumor, staging, and SUV max . The overall staging was the same by PET/CT and MRI in only 43% of the patients. The agreement was slight and statistically insignificant (kappa00.104, Table 3 ). The agreements in T and N stagings were 29% (kappa00.0870, Table 4 ) and 64% (kappa00.1667, Table 5 ), respectively. FDG PET/CT tended to give lower T and overall staging than MRI, as 8 of the 12 T4 tumors on MRI were reported as T2 or T3 on FDG PET/CT, and 8 of the 13 patients with stage IV disease on MRI were reported as stage II or III on FDG PET/CT. The difference mainly reflected the fact that MRI detected greater intracranial extension of NPC (Figs. 1,  2, 3 and 4) . Table 6 summarizes data on metastatic LNs. MRI detected significantly more bilateral cervical LNs than FDG PET/CT, as these were found in all 14 patients on MRI but in only 8 patients on FDG PET/CT (p00.03). Similarly, MRI identified more bilateral retropharyngeal LNs than FDG PET/CT (9 vs. 6 patients). MRI detected supraclavicular lymphadenopathy in one patient that was not detected by FDG PET/CT. A level IV LN was revealed by FDG PET/CT but not by MRI (Fig. 5) . There was no significant association between SUV max and staging or size of the primary tumor. There was a positive correlation between SUV max and size of the left cervical LNs measured on MRI (correlation coefficient00.78, p00.006). A similar positive correlation was seen between SUV max and size of the left retropharyngeal LNs (correlation coefficient0 0.81, p00.006). We also found some degree of correlation between SUV max and EBV VCA IgG level at diagnosis (correlation coefficient00.45), but this was not statistically significant (Fig. 6 ). Since chemotherapy might reduce FDG uptake, we analyzed the data again after exclusion of the three patients whose PET/CT scans were done soon after initiation of chemotherapy. The results were similar with and without inclusion of these three patients, except that the correlation between SUV max and the size of the left retropharyngeal LNs was not longer statistically significant (correlation coefficient00.71, p00.09). The correlation between SUV max and the size of left cervical LNs remained significant (correlation coefficient0 0.83, p00.015).
Follow-up PET/CT
Nine patients had 25 follow-up PET/CT scans. Of these scans, 24 (8 patients) had an MRI scan within 1 month for comparison. Tables 7 and 8 show the concordance between these scans. PET/CT and MRI were concordant in fourfifths of the scans. Concordance was 100% 9 months after therapy. In those who achieved remission, PET/CT showed a These jugulodigastric nodes of less than 1.1 cm were part of a cluster of nodes.
no disease 3-6 months earlier than MRI. There were no false-positive or false-negative PET/CT scans. In one patient with disease relapse who died of progressive disease, the PET/CT scan showed lung and mediastinal metastases.
Discussion
To the best of our knowledge, this is the first study evaluating FDG PET/CT in pediatric patients with NPC. The findings of previous studies of FDG PET/CT in adults were somewhat conflicting and might not be directly applicable to children. We found the concordance between FDG PET/ CT and MRI staging was not high. This is consistent with literature which indicates concordance rates of 46-68% on T and overall staging [12, 13] . Some studies have shown that MRI is superior to FDG PET and FDG PET/CT in assessing primary tumor extension [12, 13] . However, other studies have shown FDG PET/CT to be superior [5, 25, 26] . We found that the tumor usually appeared larger on MRI, possibly due to inclusion of inactive areas in measurements, leading to lower staging on FDG PET/CT. MRI may also be more sensitive for detection of subtle areas of tumor extension, for example intracranial extension, that are too small for visualization by FDG PET/CT.
Consistent with the findings of previous studies [12, 15, 27] , N staging showed better concordance between FDG PET/CT and MRI. FDG PET/CT has been reported to have higher accuracy in detecting cervical LNs than conventional imaging [6, 15, 27, 28] . Ng et al. [12] reported that FDG PET/CT was superior to MRI in revealing cervical but not retropharyngeal LNs. Tang et al. [29] concurred that FDG PET/CT is less likely to detect retropharyngeal LNs. We found that FDG PET/CT tended to underestimate both cervical and retropharyngeal LNs in children compared to MRI. On the other hand, MRI may overestimate nodal involvement based solely on size criteria. Since histology of LNs is not routinely obtained, it is not possible to determine with certainty whether MRI overestimates neoplastic involvement compared to the true depiction of tumor involvement with FDG PET/CT, or whether FDG PET/CT underestimates tumor involvement. Without histology which is considered the gold standard for diagnosis, neoplastic and non-neoplastic lymphadenopathy are difficult to distinguish, particularly in children, in whom enlarged LNs are not uncommon.
Staging by conventional imaging is associated with prognosis of NPC [30, 31] . Although FDG PET/CT tended to yield a lower stage than MRI, this might not be inappropriate because subtle intracranial extension visible on MRI but not FDG PET/CT may not affect prognosis, and the relative Fig. 5 Axial T2-weighted MR image of the neck (a) in a 15-year-old patient with NPC demonstrates two adjacent level IV LNs in the left side of the neck that do not meet the size criteria for pathological nodes, although the asymmetry and grouping of these nodes in the setting of NPC may raise some concern for metastases. A PET image obtained at the same level (b) demonstrates intense radiotracer uptake in the more lateral of the two nodes allowing a much more confident diagnosis of metastatic disease under-staging by FDG PET/CT would not have altered treatment under the current protocol had FDG PET/CT been utilized for staging. A correlation between FDG PET/CT staging and patient outcome is essential to ascertain the prognostic value of FDG PET/CT. However, this was not possible in the current study since the clinical outcome in the patients studied from initial presentation was uniformly good.
We found that SUV max of the primary tumor was higher than reported [32] [33] [34] [35] . This may be related to a higher proportion of type III histology in children, as SUV max in such tumors is higher [32, 35] . We also found that SUV max was positively correlated with the size of the LNs but not that of the primary tumor. This might reflect difference in metabolic behavior between the primary tumor and metastatic LNs, as SUV max in LNs was lower and had a wider variation. This could also reflect technical issues of activity recovery in small LNs compared with large primary tumors, as the SUV of LNs is subject to partial volume effect and thus has a wide variation. Whether SUV max is associated with tumor aggressiveness and prognosis in children is uncertain, as it was not associated with stage and we could not assess its effect on clinical outcome. Nevertheless, SUV max might increase with T stage [32] , and higher SUV max has been correlated with poorer survival [33, 36] . Patients whose LN SUV max was higher than the primary tumor SUV max also fared worse [36] .
FDG PET/CT may help in detecting distant metastasis, as seen in our study and previous studies [5] [6] [7] . However, its sensitivity and specificity in detecting metastases are difficult to evaluate, as it was not compared with conventional imaging for different sites systematically. FDG PET/CT may replace bone scan as FDG PET might be more sensitive in detecting skeletal metastases [8] .
FDG PET/CT may help in follow-up evaluation in pediatric NPC, as FDG PET/CT had fairly good concordance with MRI and had low false-positive and false-negative rates, consistent with the findings of adult studies [9-11, 34, 37, 38] . FDG PET/CT can screen the whole body in a single session and differentiate between active tumor and residual masses. FDG PET might have better sensitivity, specificity, and accuracy than MRI and result in management changes [37] . False-positive results, however, may occur because of inflammation or osteoradionecrosis [39] . On the other hand, SUV max 3 months after treatment may predict local relapse [34] , and those who are downstaged by FDG PET after chemotherapy may have better survival [40] . We found that FDG PET/CT detected tumor clearance earlier than MRI, as MRI might give a false-positive signal due to scar. While we have found FDG PET/CT a useful tool in the diagnosis and follow-up of children with NPC, a prospective evaluation with uniform diagnostic imaging, treatment and monitoring would be required.
The radiation exposure from the FDG PET/CT was quite low, approximately 10.2 mSv with our technique and equipment. This is probably of little clinical concern in the context of the radiation exposure received as a result of therapy. On the other hand, PET/MRI may be better in evaluating LN metastases. Coronal MR images would be the best for this purpose. However, currently our software only registers transverse sequences. Although these can be reformatted to coronal sections, the image quality is degraded compared to native coronal sequences. Therefore, we did not pursue this option. The utility of PET/MRI certainly warrants evaluation in future studies. Our study had several limitations. First, not all patients had a baseline FDG PET/CT scan and a concurrent MRI scan, and different patients had different imaging schedules, thus complicating the interpretation of the results. Second, the sample size was small. However, it is still the largest study of FDG PET/CT in pediatric NPC. Third, there was lack of uniformity in the technical parameters for the MRI examinations. While this could have affected the evaluation of tumor boundaries and measurements, it was not a significant factor in this investigation. Fourth, we did not have LNs detected on MRI pathologically verified. Some of the nodes that were enlarged by size criteria on MRI might not have actually been metastatic. This is where PET may have been more accurate. Finally, the FDG PET/CT technique was devised for whole-body screening, using CT parameters intended for attenuation correction and lesion localization without administration of intravenous contrast agent. Modification of the technique and CT with intravenous contrast agent enhancement for attenuation of emission FDG PET might possibly have lowered the discrepancies between PET/CT and MRI. On the other hand, intravenous contrast agent may cause beam hardening artifacts if not optimally administered.
Conclusion
In pediatric NPC, FDG PET/CT tends to yield a lower stage than MRI. It is also less sensitive in detecting bilateral cervical and retropharyngeal LN metastases based on size criteria of MRI. However, it is valuable in detecting distant metastasis and clarifying ambiguous findings on MRI. FDG PET/CT is also sensitive and specific for follow-up and enables earlier detection of disease clearance and simpler monitoring.
